SCHEMBL295841

SCHEMBL295841

C=CC(=O)N(Cc1ccccc1)Cc1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.53
TDP1 Q9NUW8 1/20 0.53
ALDH1A1 P00352 3/20 0.52
NPSR1 Q6W5P4 1/20 0.52
GAA P10253 1/20 0.51
TSHR P16473 1/20 0.50
GSTO1 P78417 1/20 0.49
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
KDM4E B2RXH2 1/20 0.49
MAPT P10636 2/20 0.47
SNCA P37840 1/20 0.47
MGLL Q99685 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.46
REN P00797 1/20 0.46
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1373021 0.94 MEN1 (0.53) LMNATDP1ALDH1A1NPSR1GAA
SCHEMBL10704105 0.93 TDP1 (0.47) LMNATDP1ALDH1A1NPSR1GAA
SCHEMBL286790 0.91 LMNA (0.64) LMNATDP1ALDH1A1GAATSHR
SCHEMBL27928642 0.91 TDP1 (0.46) LMNATDP1ALDH1A1NPSR1GAA
SCHEMBL20018650 0.89 REN (0.48) LMNATDP1ALDH1A1NPSR1GAA
SCHEMBL10532077 0.89 L3MBTL1 (0.50) LMNATDP1ALDH1A1NPSR1GAA
SCHEMBL20275523 0.87 MEN1 (0.46) LMNATDP1ALDH1A1NPSR1GAA
SCHEMBL31518843 0.87 ALDH1A1 (0.48) LMNATDP1ALDH1A1GAAMEN1
SCHEMBL14448173 0.87 LMNA (0.46) LMNATDP1ALDH1A1NPSR1GAA
SCHEMBL12863501 0.87 LMNA (0.46) LMNATDP1ALDH1A1NPSR1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 993 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122042738-A Phase transition migration process rate testing device and method for non-pure water electrolysis hydrogen production 深圳大学 2026-05-15 CN claimed
US-20250389633-A1 SYNTHETIC HUMAN CELL MIMIC PARTICLE FOR CYTOMETRIC OR COULTER DEVICE SLINGSHOT BIOSCIENCES, INC. (US) 2025-12-25 US claimed
US-20250298042-A1 ENGINEERED PARTICLES AS RED BLOOD CELL MIMICS AND COMPOSITIONS CONTAINING SAME FOR HEMATOLOGY SLINGSHOT BIOSCIENCES, INC. (US) 2025-09-25 US claimed
EP-4608872-A2 SIZE-TUNABLE SYNTHETIC PARTICLES WITH TUNABLE OPTICAL PROPERTIES AND METHODS FOR USING THE SAME FOR IMMUNE CELL ACTIVATION Slingshot Biosciences, Inc. (US) 2025-09-03 EP claimed
US-12379387-B2 Engineered particles as red blood cell mimics and compositions containing same for hematology SLINGSHOT BIOSCIENCES, INC. (US) 2025-08-05 US claimed
EP-3256850-B1 HYDROGEL PARTICLES WITH TUNABLE OPTICAL PROPERTIES AND METHODS FOR USING THE SAME SLINGSHOT BIOSCIENCES INC (US) 2025-07-09 EP claimed
US-12352679-B2 Synthetic human cell mimic particle for cytometric or coulter device SLINGSHOT BIOSCIENCES, INC. (US) 2025-07-08 US claimed
EP-4577823-A2 COMPOSITIONS AND METHODS FOR SINGLE WELL MULTIPLEXED CALIBRATION AND COMPENSATION Slingshot Biosciences, Inc. (US) 2025-07-02 EP claimed
US-20250189428-A1 COMPOSITIONS AND METHODS FOR SINGLE WELL MULTIPLEXED CALIBRATION AND COMPENSATION SLINGSHOT BIOSCIENCES, INC. (US) 2025-06-12 US claimed
US-12312595-B2 Hydrogel particles as feeder cells and as synthetic antigen presenting cells SLINGSHOT BIOSCIENCES, INC. (US) 2025-05-27 US claimed
US-20020042483-A1 High refractive index hydrogel compositions for ophthalmic implants VANDERBILT DAVID P (US) 2002-04-11 US claimed
US-20020042484-A1 High refractive index hydrogel compositions for ophthalmic implants BAUSCH & LOMB MEXICO, S.A. DE C.V. (MX) 2002-04-11 US claimed
US-20020037984-A1 High refractive index hydrogel compositions for ophthalmic implants VANDERBILT DAVID P (US) 2002-03-28 US claimed
US-6329485-B1 FOR INTRAOCULAR LENSES BAUSCH & LOMB INCORPORATED 2001-12-11 US claimed
EP-1119660-A1 CELLULOSIC SUPPORT TREATMENT MORGAN ADHESIVES COMPANY (US) 2001-08-01 EP claimed
WO-2001004418-A1 CELLULOSIC SUPPORT TREATMENT MORGAN ADHESIVES COMPANY (US) 2001-01-18 WO claimed
WO-2000034804-A1 HIGH REFRACTIVE INDEX HYDROGEL COMPOSITIONS FOR OPHTHALMIC IMPLANTS BAUSCH & LOMB SURGICAL, INC. (US) 2000-06-15 WO claimed
EP-0370547-B1 Graft stabilising and prestabilising copolymers, their preparation, process to obtain polymer-polyol dispersions and process to obtain polyurethane foams NEW CARBOCHIM SA (BE) 1994-03-16 EP claimed
US-5081180-A Graft copolymers as polyether stabilizers THE DOW CHEMICAL COMPANY 1992-01-14 US claimed
EP-0370547-A1 Graft stabilising and prestabilising copolymers, their preparation, process to obtain polymer-polyol dispersions and process to obtain polyurethane foams NEW CARBOCHIM S.A. (BE) 1990-05-30 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250389633-A1 SYNTHETIC HUMAN CELL MIMIC PARTICLE FOR CYTOMETRIC OR COULTER DEVICE CD4, ICOS, CD69 LMNA 3949/4885TDP1 1737/4885ALDH1A1 3752/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.